Plant tumor-inhibiting targeting polypeptide preparation and preparation method thereof
By isolating and purifying active polypeptides targeted binding and inhibiting PD-L1 from Astragalus root, the problem of insufficient research on Astragalus polypeptides in the prior art was solved, and the effect of effectively inhibiting tumor cell proliferation was achieved, and there is great application prospect.
Patent Information
- Application Number
- CN202411146689.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There are few researches on astragalus polypeptides in the prior art, especially in the field of tumor treatment, and there are few reports on the application, and there are lack of highly effective anti-cancer Astragalus polypeptide preparations.
Two active polypeptides with targeted binding and inhibition of PD-L1 were isolated and purified from Astragalus root, and prepared by cleaning, physical crushing, supercritical CO2 extraction, enzymatic decomposition, filtration concentration and drying, to obtain broad-spectrum anti-anti-anti-spectrum Tumor activity and good biocompatible Astragalus polypeptide.
It effectively inhibits tumor cell proliferation, has great application prospects, and shows good biological compatibility and anti-tumor effects.
Smart Images

Figure CN119020440A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of tumor treatment, and more specifically, to a plant tumor-inhibiting targeted polypeptide preparation and a preparation method thereof. Background Art
[0002] In recent years, the prevention and anti-cancer effects of plants on tumors have become one of the hot topics in recent years. Specific records of tumors in traditional Chinese medicine are scattered among various diseases. Anti-tumor plants are mostly summarized in combination with the treatment of these diseases, mainly including heat-clearing and detoxifying, qi-replenishing, etc. All of them need to be taken strictly under the guidance of doctors after syndrome differentiation in traditional Chinese medicine.
[0003] Astragalus root is used as medicine, and its medicinal history is long. The earliest Chinese book "Shennong's Herbal Classic" lists Astragalus as "top grade". "Medicinal Properties Song Jue" says: "Astragalus is used as medicine, which is a tonic, has the effects of invigorating the body's vital energy, strengthening the spleen and stomach, expelling pus and relieving pain, and promoting blood circulation and curing danger. It has significant effects on spontaneous sweating due to superficial deficiency, internal injury due to qi deficiency, mental depression, weakness of the limbs, diarrhea due to spleen deficiency, excessive sweating due to physical deficiency, prolapse of the anus due to qi deficiency, prolapse of the uterus, edema and carbuncle". Ancient medicine books such as "Famous Doctors' Records" and "Compendium of Materia Medica" all believe that it has the effect of invigorating qi and replenishing deficiency. Astragalus is a tonic Chinese medicine. Raw Astragalus has the effects of invigorating qi and strengthening the exterior, promoting diuresis and reducing swelling, detoxifying and promoting muscle regeneration. Honey-roasted Astragalus has the effects of invigorating qi, nourishing blood and benefiting the middle. Modern pharmacological studies have shown that astragalus contains active peptides, saponins, sucrose, polysaccharides, multiple amino acids, folic acid, and trace elements such as selenium, zinc, and copper, which can improve the body's immune ability and have a certain auxiliary effect in fighting tumors. The dialectical use of astragalus before and after surgery can enhance the body's immunity, improve the surgical cure rate, and improve the patient's quality of life. The use of astragalus during radiotherapy and chemotherapy can reduce the toxic side effects of radiotherapy and chemotherapy, improve the efficacy of radiotherapy and chemotherapy, and enhance the patient's tolerance to radiotherapy and chemotherapy.
[0004] However, at present, there are relatively few studies on Astragalus polypeptides in the existing technology, and even fewer reports in the field of tumor treatment. Medical workers need to continue research and development to find an Astragalus polypeptide with high anti-cancer effect. Summary of the invention
[0005] In view of the technical problems existing in the prior art and in order to effectively explore the potential of anti-tumor plant applications, the present invention provides two active polypeptides that are separated and purified from the root of Astragalus for the first time and have the ability to target and inhibit PD-L1. The active polypeptides have a broad spectrum of anti-tumor activity, can effectively inhibit the proliferation of tumor cells, and have good biological compatibility, thus having great application prospects.
[0006] Specifically, the present invention first provides a method for preparing a plant-based tumor-suppressing targeting polypeptide, comprising the following steps:
[0007] 1) Preparation: Wash the Astragalus root, cut it into pieces, and blow dry it at room temperature for later use;
[0008] 2) Physical crushing: Put the astragalus root pieces obtained in step 1) into a wall-breaking machine and crush them into fine particles;
[0009] 3) subjecting the astragalus powder obtained in step 2) to supercritical CO2 extraction for 6-12 hours to obtain defatted astragalus powder;
[0010] 4) mixing the defatted astragalus powder obtained in step 3) with water in a weight ratio of 1:10-20, adjusting the pH value to 8.5-10.5, heating to 50-70° C., treating with ultrasonic microwaves for 10-20 min, filtering, and collecting the filtrate;
[0011] 5) Composite enzymatic hydrolysis: Add composite protease with a final concentration of 20-50% to the filtrate of step 4), continue stirring and enzymatic hydrolysis for 5-10 hours, and heat to 95-100° C. for 10-15 minutes to inactivate the enzyme, and then centrifuge and separate the supernatant to obtain the astragalus enzymatic hydrolyzate;
[0012] 6) Filtration and concentration: Filter the astragalus hydrolyzate in step 5) using an ultrafiltration membrane to retain polypeptide molecules with a molecular weight cutoff of 4000-5000Da; vacuum concentrate the filtered astragalus polypeptide to a concentration of 10-18°Bé to obtain an astragalus polypeptide concentrate;
[0013] 7) Identification of Astragalus polypeptides: The Astragalus polypeptide concentrate from step 6) is sequenced;
[0014] 8) Purity identification of Astragalus polypeptide: The Astragalus polypeptide concentrate is transferred to a spray dryer, and the air inlet temperature is 90-100° C. and the air outlet temperature is 70-80° C. for drying until the water content of the Astragalus polypeptide dry powder is no more than 5%, and the dry powder is collected to obtain the Astragalus polypeptide.
[0015] Preferably, in step 1), the size of the astragalus fragments is 0.5 to 1.0 cm in length, width and height.
[0016] Preferably, the cell breaking conditions in step 2) are 50000-100000 r / min for 5-30 min.
[0017] Preferably, the composite protease in step 5) is a combination of neutral protease and papain, and the usage ratio of the two is (3-5):(2-9).
[0018] Preferably, the enzymolysis conditions in step 5) are continuous stirring at a temperature of 28-45°C for 12-24 hours.
[0019] Preferably, step 5) further comprises heating the enzymatic hydrolysate to 90-100° C. and maintaining the temperature for 10-30 minutes to inactivate the enzyme.
[0020] Preferably, the vacuum concentration in step 6) is performed to a concentration of 14° Bé.
[0021] Preferably, in step 2), Ob itrap Fusion Lumos mass spectrometer sequencing is performed.
[0022] Preferably, the amino acid sequences of the Astragalus polypeptides identified in step 8) are shown in SEQ ID NO. 1-2.
[0023] Another object of the present invention is to provide a plant tumor suppressor targeting polypeptide, characterized in that the amino acid sequence of the polypeptide is shown in SEQ ID NO.1-2 in sequence.
[0024] Preferably, the polypeptide has the ability to target and inhibit PD-L1.
[0025] Furthermore, the present invention also provides an anti-tumor preparation, characterized in that the preparation uses astragalus polypeptide as a main active ingredient, and the amino acid sequence of the astragalus polypeptide is any one or a combination of SEQ ID NO.1-2.
[0026] Furthermore, the present invention also provides the use of the Astragalus polypeptide in the preparation of an anti-tumor preparation, characterized in that the amino acid sequence of the Astragalus polypeptide is any one or a combination of SEQ ID NO.1-2.
[0027] Preferably, the tumor includes but is not limited to breast cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, gastric cancer, esophageal cancer, colon cancer, bladder cancer, kidney cancer, prostate cancer, ovarian cancer, uterine cancer, etc.
[0028] Furthermore, the present invention also provides a use of the Astragalus polypeptide in the preparation of a PD-L1 inhibitor, characterized in that the amino acid sequence of the Astragalus polypeptide is any one or a combination of SEQ ID NO.1-2.
[0029] The advantages of the present invention are as follows: the present invention separates and purifies for the first time from the root of Astragalus to obtain two active polypeptides that have the ability to target and inhibit PD-L1, the active polypeptides have a broad spectrum of anti-tumor activity, can effectively inhibit the proliferation of tumor cells, and have good biological compatibility, and have great application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 This is a graph showing the results of analyzing the proliferation activity of the Astragalus polypeptide of the present invention on tumor cells. DETAILED DESCRIPTION
[0031] The present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can understand the present invention more clearly.
[0032] The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. Based on the specific embodiments of the present invention, all other embodiments obtained by ordinary technicians in the field without creative work belong to the protection scope of the present invention.
[0033] In the examples of the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art; in the examples of the present invention, unless otherwise specified, the technical means used are conventional means well known to those skilled in the art.
[0034] Example 1 Preparation of Astragalus polypeptide
[0035] The preparation method of Astragalus polypeptide comprises the following steps:
[0036] 1) Preparation: Wash the Astragalus root, cut it into pieces, and blow dry it at room temperature for later use;
[0037] 2) Physical crushing: Put the astragalus root pieces obtained in step 1) into a wall-breaking machine and crush them into fine particles;
[0038] 3) subjecting the astragalus powder obtained in step 2) to supercritical CO2 extraction for 6 hours to obtain defatted astragalus powder;
[0039] 4) mixing the defatted astragalus powder obtained in step 3) with water in a weight ratio of 1:10, adjusting the pH value to 8.5, heating to 50° C., treating with ultrasonic microwaves for 10 min, filtering, and collecting the filtrate;
[0040] 5) Composite enzymatic hydrolysis: Add a composite protease with a final concentration of 20% to the filtrate of step 4), continue stirring for enzymatic hydrolysis for 5 hours, and heat to 95°C for 10 minutes to inactivate the enzyme, then centrifuge and separate the supernatant to obtain an astragalus hydrolysate; wherein the composite protease is a combination of neutral protease and papain, and the dosage ratio of the two is 3:2; the enzymatic hydrolysis conditions are continuous stirring for enzymatic hydrolysis at a temperature of 28°C for 12 hours.
[0041] 6) Filtration and concentration: The astragalus hydrolyzate in step 5) is filtered using an ultrafiltration membrane with a molecular weight cutoff of 4000-5000Da polypeptide molecules; the filtered astragalus polypeptide is vacuum concentrated to a concentration of 14°Bé to obtain an astragalus polypeptide concentrate;
[0042] 7) Identification of Astragalus polypeptides: The Astragalus polypeptide concentrate from step 6) was sequenced by Obitrap Fusion Lumos mass spectrometer;
[0043] 8) Purity identification of Astragalus polypeptide: The Astragalus polypeptide concentrate was transferred to a spray dryer, and dried at an inlet air temperature of 100° C. and an outlet air temperature of 80° C. until the moisture content of the Astragalus polypeptide dry powder was about 4.57%, and the dry powder was collected to obtain the Astragalus polypeptide.
[0044] The results showed that two kinds of Astragalus polypeptides were obtained through sequencing and identification analysis, and the sequences were shown in SEQ ID NO.1-2. The purity of the obtained Astragalus polypeptides was determined by HPLC to be more than 98.6%.
[0045] Example 2 SPR analysis of Astragalus polypeptide and PD-L1
[0046] Binding affinity was analyzed by multi-cycle kinetics / affinity. Taking the Biocore T200 biomolecular interaction analysis system as an example, the analyte concentration range was optimized by manual injection, and the fixed PD-L1 was flowed at a flow rate of 20 μl / min, binding for 100 s, dissociation for 120 s, 10 mM glycine (2.0, 2.5, 3.0) was used to regenerate the chip surface for 30 s, and the obtained RU was recorded. The obtained sensorgram data were evaluated using the Kinetics / Affinity tool of the Bioevolution analysis software, and the kinetic model was fitted using the 1:1 Lambmuir model analysis, and the equilibrium dissociation constant (KD) was calculated to determine the ability of the modulator to interact with PD-1. The smaller the KD (Kd / Ka) value, the greater the degree of binding and the less the degree of dissociation of the analyte with PD-L1, and the stronger the affinity between PD-L1. The KD of the two Astragalus peptides that interact with PD-L1 are listed in Table 1. The results showed that the two Astragalus peptides had different degrees of affinity with PD-L1, indicating that the Astragalus peptides have the potential to become PD-L1 inhibitors.
[0047] Table 1 Affinity of Astragalus peptides for PD-L1
[0048] Analytes KD(μM) PD-1 0.8256±0.0042 SEQ ID NO.1 2.0155±1.0240 SEQ ID NO.2 2.3658±1.2358
[0049] Example 3 Analysis of the anti-tumor efficacy of Astragalus polypeptide
[0050] Breast cancer, lung cancer, and liver cancer were used as the research objects to analyze the anti-tumor effect of Astragalus polypeptide. The details are as follows: breast cancer cells MCF7, lung cancer cells A549, and hepatocellular carcinoma HEPG2 were cultured and 1×10 5Cells / well were inoculated in a 96-well cell culture plate, 100 μL per well, and placed in an incubator for 12 hours for adhesion treatment. Then, the Astragalus polypeptide solution shown in SEQ ID NO.1-2 was prepared with a final concentration of 20 μg / mL in the cell culture medium, and added to the 96-well plate one by one, 100 μL per well, and incubated together for 12 hours. Among them, treatment group 1 was the Astragalus polypeptide shown in SEQ ID NO.1, treatment group 2 was the Astragalus polypeptide shown in SEQ ID NO.2, the control group was added with an equal amount of cell culture medium, and the blank group was a simple culture medium. The proliferation activity of tumor cells was analyzed using the MTT cell proliferation and cytotoxicity detection kit (purchased from Shangbao Biology, item number 20311).
[0051] The results are as follows Figure 1 As shown, the two kinds of Astragalus polypeptides prepared by the present invention have good activity in inhibiting tumor cell proliferation, especially the Astragalus polypeptide shown in SEQ ID NO.1 has the most obvious inhibitory effect on tumor cell proliferation.
[0052] It is necessary to point out that the above embodiments are limited to further elaboration and explanation of the technical solution of the present invention, and are not further limitations of the technical solution of the present invention. The method of the present invention is only a preferred implementation scheme, and is not used to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for preparing a plant-based tumor suppressor targeting polypeptide, characterized in that: The following steps are involved: 1) Preparation: Wash the Astragalus root, cut it into pieces, and blow dry it at room temperature for later use; 2) Physical crushing: Put the astragalus root pieces obtained in step 1) into a wall-breaking machine and crush them into fine particles; 3) subjecting the astragalus powder obtained in step 2) to supercritical CO2 extraction for 6-12 hours to obtain defatted astragalus powder; 4) mixing the defatted astragalus powder obtained in step 3) with water in a weight ratio of 1:10-20, adjusting the pH value to 8.5-10.5, heating to 50-70° C., treating with ultrasonic microwaves for 10-20 min, filtering, and collecting the filtrate; 5) Composite enzymatic hydrolysis: Add composite protease with a final concentration of 20-50% to the filtrate of step 4), continue stirring and enzymatic hydrolysis for 5-10 hours, and heat to 95-100° C. for 10-15 minutes to inactivate the enzyme, and then centrifuge and separate the supernatant to obtain the astragalus enzymatic hydrolyzate; 6) Filtration and concentration: The astragalus hydrolyzate is filtered by an ultrafiltration membrane as in step 5, with a molecular weight cutoff of 4000-5000Da polypeptide molecules; the filtered astragalus polypeptide is vacuum concentrated to a concentration of 10-18° Bé to obtain an astragalus polypeptide concentrate; 7) Identification of Astragalus polypeptides: The Astragalus polypeptide concentrate from step 6) was sequenced; 8) Purity identification of Astragalus polypeptide: The Astragalus polypeptide concentrate is transferred to a spray dryer, and the air inlet temperature is 90-100° C. and the air outlet temperature is 70-80° C. for drying until the water content of the Astragalus polypeptide dry powder is no more than 5%, and the dry powder is collected to obtain the Astragalus polypeptide.
2. The method according to claim 1, characterized in that In step 1), the size of the astragalus fragments is 0.5 to 1.0 cm in length, width and height.
3. The method according to claim 1, characterized in that Step 2) The wall breaking condition is 50000-100000 r / min for 5-30 min.
4. The method according to claim 1, characterized in that Step 5) The composite protease is a combination of neutral protease and papain, and the usage ratio of the two is (3-5):(2-9).
5. The method according to claim 1, characterized in that The enzymatic hydrolysis conditions in step 5) are continuous stirring at a temperature of 28-45°C for 12-24 hours.
6. The method according to claim 1, characterized in that Step 5) further includes heating the enzymatic hydrolysate to 90-100° C. and maintaining the temperature for 10-30 minutes to inactivate the enzyme.
7. The method according to claim 1, characterized in that The mixture was concentrated in vacuo in step 6) to a concentration of 14° Bé.
8. The method according to claim 1, characterized in that The amino acid sequences of the Astragalus polypeptides identified in step 8) are shown in SEQ ID NO. 1-2.
9. A plant-based tumor suppressor targeting polypeptide, characterized in that: The amino acid sequences of the polypeptides are shown in SEQ ID NO.1-2.
10. An anti-tumor preparation, characterized in that: The preparation uses astragalus polypeptide as the main active ingredient, and the amino acid sequence of the astragalus polypeptide is any one or a combination of SEQ ID NO. 1-2.
11. Use of Astragalus polypeptide in the preparation of anti-tumor preparations or PD-L1 inhibitors, characterized in that: The amino acid sequence of the Astragalus polypeptide is any one or a combination of SEQ ID NO. 1-2.
Citation Information
Patent Citations
A method for preparing an autoimmune disease vaccine derived from preactivated antigen-presenting cells and its application.
CN114931633A
Astragalus polysaccharide microneedle composition with oncolytic immune function, microneedle and preparation method and application thereof
CN117582486A
